Yu-wen Cai

P.R. China
Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer.

Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer.

Journal: Cell reports. Medicine
Published: February 25, 2026

Multi-omics analysis reveals comprehensive aberrant protein and phosphorylation characteristics in breast cancer and paired metastatic lymph nodes.

Multi-omics analysis reveals comprehensive aberrant protein and phosphorylation characteristics in breast cancer and paired metastatic lymph nodes.

Journal: Protein & cell
Published: August 13, 2025

Multi-omics Analysis Reveals Comprehensive Aberrant Protein and Phosphorylation Characteristics in Breast Cancer and Paired Metastatic Lymph Nodes.

Multi-omics Analysis Reveals Comprehensive Aberrant Protein and Phosphorylation Characteristics in Breast Cancer and Paired Metastatic Lymph Nodes.

Journal: Protein & cell
Published: August 13, 2025

Breast cancer: pathogenesis and treatments.

Breast cancer: pathogenesis and treatments.

Journal: Signal transduction and targeted therapy
Published: July 21, 2024

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.

Journal: The Journal of clinical investigation
Published: June 05, 2024

Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer.

Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer.

Journal: Cell reports. Medicine
Published: May 26, 2023

Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination.

Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 18, 2022

Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis.

Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis.

Journal: Frontiers in immunology
Published: April 13, 2022

De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.

De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.

Journal: Cancer
Published: September 08, 2021

Estrogen receptor-low breast cancer: Biology chaos and treatment paradox.

Estrogen receptor-low breast cancer: Biology chaos and treatment paradox.

Journal: Cancer communications (London, England)
Published: March 06, 2021
Showing 1-10 of 10

Last Updated: 09/26/2026